BridgeBio Pharma (NASDAQ: BBIO) shares rose following the announcement of positive results from its late-stage study of BBP-418. The study focused on patients with limb-girdle muscular dystrophy type 2I/R9.
The trial successfully met all its primary and secondary endpoints, demonstrating a safety profile consistent with expectations. This promising outcome highlights the potential of BBP-418 as a treatment option for this rare muscular dystrophy.
https://seekingalpha.com/news/4508878-bridgebio-rises-after-late-stage-muscular-dystrophy-trial-success?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news